Outgoing Nike CEO John Donahue made strategic missteps, most especially losing his team's winning spirit.. In-coming 32-year Nike veteran Elliott Hill will restore it.
As part of a well-rounded, diversified portfolio, blue-chip stocks should be a cornerstone of your investment strategy. They ...
Beyond MariTide, Amgen has a rich pipeline with more than 30 phase 3 programs. Some are for existing medicines seeking label expansions, such as Lumakras and Amjevita, a rheumatoid arthritis medicine.